Every 10-Q that Thermo Fisher Scientific Inc. (TMO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TMO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TMO filings page.
Thermo Fisher Scientific Inc. reported Q2 2026 revenue of $11,994 million, up 10% year over year (5% organic). GAAP operating income rose to $2,087 million with a 17.4% margin, while adjusted operating income reached $2,735 million with a 22.8% margin. GAAP diluted EPS was $4.68, up 9%, and adjusted EPS $6.03, up 13%.
Growth was broad-based: Laboratory Products and Biopharma Services revenue increased 12%, Life Sciences Solutions 13%, Analytical Instruments 7% and Specialty Diagnostics 6%, all with margin expansion supported by productivity initiatives. Remaining performance obligations totaled $29.70 billion, about 52% expected to convert to revenue within 12 months.
For the first six months of 2026, cash from operations was $3,317 million and free cash flow $2,503 million. The company used $8,872 million on acquisitions, mainly the $9,098 million Clario Holdings purchase, and $4,000 million on share repurchases, reducing cash to $4,064 million and increasing total debt to $42,549 million. It agreed to sell its microbiology business for approximately $1.075 billion and recorded $147 million of restructuring and other costs year to date, with additional charges of about $220 million expected, primarily in 2026.
Thermo Fisher Scientific reported Q1 2026 revenue of $11.01B, up 6% year over year, with organic revenue growth of 1%. GAAP operating income was $1.86B and diluted EPS rose to $4.43 from $3.98, helped by a low 4.0% effective tax rate.
The company generated free cash flow of $825M and ended the quarter with $3.25B in cash and $43.16B of total debt. It closed the $9.10B acquisition of Clario to expand clinical research offerings and agreed to sell its microbiology business for about $1.08B. Thermo Fisher also repurchased $3.0B of stock and recorded $49M of restructuring costs, with about $290M of additional actions identified, mainly in Laboratory Products and Biopharma Services.
Thermo Fisher Scientific (TMO) reported Q3 2025 results. Total revenues were $11,122 million, up from $10,598 million a year ago, with product revenue at $6,489 million and service revenue at $4,633 million. Diluted EPS was $4.27 versus $4.25, and operating income reached $1,941 million.
Year to date, operating cash flow was $4,361 million versus $5,377 million in 2024, reflecting working capital outflows. The balance sheet shows cash and equivalents of $1,982 million and long-term obligations of $31,857 million. The company issued additional senior notes in October totaling $2,500 million. Remaining performance obligations were $26.46 billion, with approximately 53% expected to be recognized within 12 months.
By business in Q3: Life Sciences Solutions revenue was $2,588 million, Analytical Instruments $1,893 million, Specialty Diagnostics $1,174 million, and Laboratory Products and Biopharma Services $5,970 million. The company recorded $135 million of restructuring and other costs in Q3 ($316 million year to date) and actions in 2025 affected about 4% of its workforce. Share repurchases were $2,963 million year to date; dividends paid were $474 million.
Thermo Fisher Scientific’s Q2-25 results show modest growth, lower margins and weaker cash conversion.
Total revenue rose 3% YoY to $10.86 b; product sales +1%, services +5%. Operating income edged up 1% to $1.83 b but margin slipped 40 bp to 16.9% after $82 m of restructuring charges. Net income attributable to TMO increased 4.5% to $1.62 b; diluted EPS climbed 6% to $4.28.
For six months, revenue reached $21.22 b (+1.6%) and EPS $8.26 (+10%). Operating cash flow fell 34% to $2.12 b as inventories (+12%) and receivables (+5%) expanded. The company repurchased $2.0 b of shares, paid $311 m in dividends and issued $2.84 b of new debt, lifting total borrowings to $35.3 b (par) while cash rose to $4.58 b.
Segment revenue YoY: Life Sciences Solutions +6% ($2.50 b); Analytical Instruments −3% ($1.73 b); Specialty Diagnostics +1% ($1.13 b); Laboratory Products & Biopharma Services +4% ($6.00 b). Growth came from North America (+3%) and Europe (+6%); Asia-Pacific declined 3%.
The effective tax rate dropped to 5.6% YTD (vs 12.2%) thanks to a $153 m deferred-tax benefit on intra-entity transfers. Management expects another ~$140 m of restructuring, mainly in Laboratory Products.
Investor focus: steady EPS aided by tax gains, soft operating margin, cash-flow pressure, and higher leverage partially offset by strong liquidity.